Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in St. Poelten – page 6

95 clinical trials in St. Poelten, Austria across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

St. Poelten at a glance
95
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

95 trials in St. Poelten

Open in trial search

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Kite Pharma Inc.

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in St. Poelten

What the registry says about research in the country

01 Cardiovascular Diseases

The cardiovascular diseases research activity in St. Pölten focuses on improving outcomes for people with high-risk heart and vascular conditions. Trials are examining whether new approaches can better reduce major cardiovascular events and ease the burden of complex heart disease.

  • Atherosclerotic cardiovascular disease
  • Elevated lipoprotein(a)
  • Hypertrophic cardiomyopathy

These studies aim to test treatment effectiveness and lower the risk of serious complications in patients with difficult-to-manage cardiovascular conditions.

02 Eye Diseases

Research in eye diseases is centered on neovascular age-related macular degeneration, with an emphasis on making care more practical in everyday clinical settings. The work reflects a strong interest in improving how patients are monitored and treated.

  • Neovascular AMD
  • Real-world treatment assessment

In St. Pölten, this area of research is helping evaluate ways to support better eye care while reducing treatment burden for patients and clinics.

03 Immune System Diseases

Immune system diseases are represented by trials in allergic rhinoconjunctivitis and chronic hepatitis D infection. These studies are exploring new options to manage immune-related conditions and improve symptom control.

  • Birch pollen-induced allergic rhinoconjunctivitis
  • Chronic hepatitis D infection

The research is designed to assess whether emerging therapies can offer better relief or disease control for patients living with persistent immune-driven illnesses.

04 Neoplasms

Neoplasm research in St. Pölten spans both solid tumors and advanced cancer care, including studies in melanoma, hepatocellular carcinoma, and metastatic pancreatic ductal adenocarcinoma. The goal is to improve treatment effectiveness and survival in cancers that can be hard to treat.

  • Melanoma
  • Intermediate-stage hepatocellular carcinoma
  • Metastatic pancreatic ductal adenocarcinoma

These trials are testing new cancer treatment strategies and comparing them with established care to find better options for patients.

05 Virus Diseases

Work in virus diseases is addressing chronic hepatitis D, a serious viral infection that can lead to long-term liver damage. The studies are focused on finding more effective ways to control the disease.

  • Chronic hepatitis D infection

This area of research is aimed at evaluating new therapies against current treatment options and improving care for patients with persistent viral illness.

06 Psychiatry and Psychology

Clinical trials in psychiatry and psychology are centered on mild to moderate major depressive disorder. The research is looking at whether new treatment options can better reduce depressive symptoms and support recovery.

  • Mild to moderate major depressive disorder

These studies are intended to clarify treatment benefit and help identify therapies that may offer meaningful relief for people living with depression.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.